{
    "patient": {
        "Name": "Jose Petty",
        "DateOfBirth": "1969-10-10",
        "Sex": "Male",
        "Diagnosis": "Acute lymphocytic leukemia (ALL)",
        "BodyPart": "Leukemia",
        "Physician": "Dr. Carla Bird",
        "TreatingInstitution": "Lee-Ramirez"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Leukemia",
            "CollectedDate": "2023-08-10",
            "ReceivedDate": "2023-08-13",
            "TumorPercentage": "37%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-08-12",
            "ReceivedDate": "2023-08-13"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.D463H Spliceregionvariant-GOF",
                "VariantAlleleFraction": "24.12%"
            },
            {
                "Gene": "JAK2",
                "DNA Alteration": "c.2792A>G",
                "GeneMutation": "p.M929I Nonsense-GOF",
                "VariantAlleleFraction": "27.28%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "FGFR1",
                "DNA Alteration": "c.1966A>G",
                "GeneMutation": "p.K656E Nonsense-GOF",
                "VariantAlleleFraction": "25.83%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "FGFR2",
            "IDH1",
            "TOP2A"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "9 m/Mb",
            "Tmbpercentile": "5%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Stable"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "HSP90B1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.I66T Spliceregionvariant-LOF",
                "VariantAlleleFraction": "8.77%"
            },
            {
                "Gene": "BLM",
                "DNA Alteration": "c.2207_2212delinsTAGATTC",
                "GeneMutation": "p.Y736fs*4 Nonsense-GOF",
                "VariantAlleleFraction": "15.44%"
            },
            {
                "Gene": "PHF6",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R225X Nonsense-LOF",
                "VariantAlleleFraction": "8.08%"
            },
            {
                "Gene": "MYCN",
                "DNA Alteration": "c.131_132delinsTT",
                "GeneMutation": "p.P44L Frameshift-GOF",
                "VariantAlleleFraction": "1.52%"
            },
            {
                "Gene": "KLF1",
                "DNA Alteration": "c.892G>C",
                "GeneMutation": "p.M39L Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "5.52%"
            },
            {
                "Gene": "PTCH1",
                "DNA Alteration": "c.3583A>T",
                "GeneMutation": "p.T1195S Frameshift-GOF",
                "VariantAlleleFraction": "3.41%"
            }
        ],
        "Germline": [
            {
                "Gene": "NOTCH1",
                "DNA Alteration": "c.7398_7399insAGGGACCG",
                "GeneMutation": "p.G1196D Nonsense-GOF",
                "Condition": "realize"
            },
            {
                "Gene": "KLF1",
                "DNA Alteration": "c.892G>C",
                "GeneMutation": "p.M39L Stopgain-LOF",
                "Condition": "deal"
            }
        ]
    },
    "low coverage regions": [
        "SDHB"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.D463H Spliceregionvariant-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "24.12%"
            },
            {
                "Gene": "JAK2",
                "DNA Alteration": "c.2792A>G",
                "GeneMutation": "p.M929I Nonsense-GOF",
                "description": "TP53 encodes a protein that is a transcription factor that regulates the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair. TP53 is a tumor suppressor gene that is mutated in many cancers. Mutations in TP53 are associated with cancer progression.",
                "VariantAlleleFraction": "27.28%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "FGFR1",
                "DNA Alteration": "c.1966A>G",
                "GeneMutation": "p.K656E Nonsense-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "25.83%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-08-10"
    },
    "other": {
        "ReportId": "9846",
        "ReportDate": "2023-08-16",
        "SignedBy": "Carla Bird",
        "Supervisor": "Dr. Kevin Thompson"
    }
}